Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cash & Current Investments: 2009-2024

Historic Cash & Current Investments for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Dec 2024 value amounting to $374.6 million.

  • Vanda Pharmaceuticals' Cash & Current Investments fell 21.93% to $293.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 13.68%. This contributed to the annual value of $374.6 million for FY2024, which is 3.51% down from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Cash & Current Investments of $374.6 million as of FY2024, which was down 3.51% from $388.3 million recorded in FY2023.
  • Vanda Pharmaceuticals' 5-year Cash & Current Investments high stood at $466.9 million for FY2022, and its period low was $367.7 million during FY2020.
  • Its 3-year average for Cash & Current Investments is $409.9 million, with a median of $388.3 million in 2023.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first increased by 17.82% in 2020, then fell by 16.83% in 2023.
  • Vanda Pharmaceuticals' Cash & Current Investments (Yearly) stood at $367.7 million in 2020, then increased by 17.70% to $432.8 million in 2021, then rose by 7.87% to $466.9 million in 2022, then dropped by 16.83% to $388.3 million in 2023, then dropped by 3.51% to $374.6 million in 2024.